ArticlePloS one2018
Machine learning model combining features from algorithms with different analytical methodologies to detect laboratory-event-related adverse drug reaction signals.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Methods for drug safety signal detection using routinely collected observational electronic health care data: A systematic review.Pharmacoepidemiology and drug safety · 2023Pooled it
- Artificial Intelligence in Pharmacoepidemiology: A Systematic Review. Part 1-Overview of Knowledge Discovery Techniques in Artificial Intelligence.Frontiers in pharmacology · 2020Pooled it
- Integrating clinical decision support systems, nursing vigilance, and physician prescribing patterns to reduce preventable adverse drug events: a structured evidence-based narrative review on human-AI interface in medication safety.Frontiers in digital health · 2026Review
- Article
- Artificial Intelligence: Applications in Pharmacovigilance Signal Management.Pharmaceutical medicine · 2025Review
- Artificial intelligence in pharmacovigilance: advancing drug safety monitoring and regulatory integration.Therapeutic advances in drug safety · 2025Review
- Applying AI to Structured Real-World Data for Pharmacovigilance Purposes: Scoping Review.Journal of medical Internet research · 2024Article
- Optimal Significance Levels and Sample Sizes for Signal Detection Methods Based on Non-constant Hazards.Drug safety · 2024Article
- Article
- Use of Electronic Health Record Data for Drug Safety Signal Identification: A Scoping Review.Drug safety · 2023Article
- Prediction of Prednisolone Dose Correction Using Machine Learning.Journal of healthcare informatics research · 2023Article
- Finding Potential Adverse Events in the Unstructured Text of Electronic Health Care Records: Development of the Shakespeare Method.JMIRx med · 2021Article
- Has the Flood Entered the Basement? A Systematic Literature Review about Machine Learning in Laboratory Medicine.Diagnostics (Basel, Switzerland) · 2021Review
- Artificial Intelligence in Pharmacoepidemiology: A Systematic Review. Part 2-Comparison of the Performance of Artificial Intelligence and Traditional Pharmacoepidemiological Techniques.Frontiers in pharmacology · 2020Article
- Identifying medication harm in hospitalised patients: a bimodal, targeted approach.Therapeutic advances in drug safety · 2020Article
- Combining the Power of Artificial Intelligence with the Richness of Healthcare Claims Data: Opportunities and Challenges.PharmacoEconomics · 2019Article
- Article
- FLOating-Window Projective Separator (FloWPS): A Data Trimming Tool for Support Vector Machines (SVM) to Improve Robustness of the Classifier.Frontiers in genetics · 2018Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe importance of identifying and evaluating adverse drug reactions (ADRs) has been widely recognized. Many studies have developed algorithms for ADR signal detection using electronic health record (EHR) data. In this study, we propose a machine learning (ML) model that enables accurate ADR signal detection by integrating features from existing algorithms based on inpatient EHR laboratory results. MATERIALS AND
methodsTo construct an ADR reference dataset, we extracted known drug-laboratory event pairs represented by a laboratory test from the EU-SPC and SIDER databases. All possible drug-laboratory event pairs, except known ones, are considered unknown. To detect a known drug-laboratory event pair, three existing algorithms-CERT, CLEAR, and PACE-were applied to 21-year inpatient EHR data. We also constructed ML models (based on random forest, L1 regularized logistic regression, support vector machine, and a neural network) that use the intermediate products of the CERT, CLEAR, and PACE algorithms as inputs and determine whether a drug-laboratory event pair is associated. For performance comparison, we evaluated the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), F1-measure, and area under receiver operating characteristic (AUROC).
resultsAll measures of ML models outperformed those of existing algorithms with sensitivity of 0.593-0.793, specificity of 0.619-0.796, NPV of 0.645-0.727, PPV of 0.680-0.777, F1-measure of 0.629-0.709, and AUROC of 0.737-0.816. Features related to change or distribution of shape were considered important for detecting ADR signals.
conclusionsImproved performance of ML models indicated that applying our model to EHR data is feasible and promising for detecting more accurate and comprehensive ADR signals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.